
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9232363/publications.pdf Version: 2024-02-01



LUICI ALBERTO PINI

#	Article	IF	CITATIONS
1	A case-control study of visually evoked postural responses in childhood with primary headaches. Neurological Sciences, 2020, 41, 305-311.	0.9	4
2	ldentification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. Cephalalgia, 2020, 40, 1070-1078.	1.8	6
3	Nabilone administration in refractory chronic diarrhea: a case series. BMC Gastroenterology, 2019, 19, 105.	0.8	13
4	Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication–overuse headache. BMC Neurology, 2019, 19, 239.	0.8	3
5	Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 242, 63-67.	0.5	3
6	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	2.5	7
7	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	1.4	24
8	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacological Research, 2018, 133, 65-76.	3.1	30
9	Response to: "Drugs for treatment for alcohol use disorders expose to interactions with others … for little benefit if any― Pharmacological Research, 2018, 134, 220.	3.1	Ο
10	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study. European Journal of Clinical Pharmacology, 2018, 74, 1427-1436.	0.8	27
11	Urinary Proteomics in Biomarker Discovery of Kidney-Related Disorders: Diabetic Nephropathy and Drug-Induced Nephrotoxicity in Chronic Headache. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 290-297.	0.7	3
12	Serum protein changes in a rat model of chronic pain show a correlation between animal and humans. Scientific Reports, 2017, 7, 41723.	1.6	26
13	Spotlight on Anti GRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development, 2017, 6, 534-547.	0.8	56
14	Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. Journal of Headache and Pain, 2017, 18, 71.	2.5	34
15	A Critical Evaluation on MOH Current Treatments. Current Treatment Options in Neurology, 2017, 19, 32.	0.7	17
16	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. Journal of Headache and Pain, 2017, 18, 66.	2.5	27
17	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2017, 8, 586.	1.1	42
18	A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants. Journal of Headache and Pain, 2016, 17, 114.	2.5	38

#	Article	IF	CITATIONS
19	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. Journal of Headache and Pain, 2016, 17, 48.	2.5	49
20	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91.	1.7	36
21	O015. Evaluation of the genetic polymorphism of the α3 (CHRNA3) and α5 (CHRNA5) nicotinic receptor subunits, in patients with cluster headache. Journal of Headache and Pain, 2015, 16, A88.	2.5	4
22	Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache. Journal of Headache and Pain, 2015, 16, 559.	2.5	14
23	P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse. Journal of Headache and Pain, 2015, 16, A183.	2.5	Ο
24	Proteomic research of proteins involved in pain expression in an animal model of chronic pain. Journal of Headache and Pain, 2015, 16, A8.	2.5	0
25	Children's Headache: Drawings in the Diagnostic Work Up. Neuropediatrics, 2015, 46, 261-268.	0.3	15
26	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. European Neuropsychopharmacology, 2014, 24, 1289-1297.	0.3	55
27	Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey. Journal of Headache and Pain, 2013, 14, 48.	2.5	35
28	An unusual case report on the possible role of Warfarin in migraine prophylaxis. SpringerPlus, 2013, 2, 48.	1.2	9
29	A preliminary study on the relationship between central auditory processing and childhood primary headaches in the intercritical phase. Journal of Headache and Pain, 2013, 14, 69.	2.5	5
30	The omics in migraine. Journal of Headache and Pain, 2013, 14, 55.	2.5	30
31	Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. Journal of Headache and Pain, 2013, 14, 6.	2.5	15
32	Comparison of tolerability and efficacy of a combination of paracetamolÂ+Âcaffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. Journal of Headache and Pain, 2012, 13, 669-675.	2.5	22
33	Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. Journal of Headache and Pain, 2012, 13, 677-684.	2.5	67
34	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	2.5	129
35	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. Journal of Headache and Pain, 2012, 13, 401-406.	2.5	31
36	Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. Journal of Headache and Pain, 2012, 13, 45-52.	2.5	15

#	Article	IF	CITATIONS
37	Basal cutaneous pain threshold in headache patients. Journal of Headache and Pain, 2011, 12, 303-310.	2.5	30
38	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. Journal of Headache and Pain, 2011, 12, 361-368.	2.5	47
39	An emerging problem in clinical practice: how to treat chronic headache patients. Internal and Emergency Medicine, 2011, 6, 9-10.	1.0	1
40	Preclinical pharmacological profile of the selective 5-HT1 _F receptor agonist lasmiditan. A comment. Cephalalgia, 2011, 31, 1061-1061.	1.8	2
41	Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. Cephalalgia, 2011, 31, 543-549.	1.8	16
42	Lack of association between five serotonin metabolism-related genes and medication overuse headache. Journal of Headache and Pain, 2010, 11, 53-58.	2.5	10
43	The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats. Life Sciences, 2010, 86, 510-517.	2.0	9
44	Future drugs for migraine. Internal and Emergency Medicine, 2009, 4, 361-362.	1.0	1
45	Differential involvement of opioidergic and serotonergic systems in the antinociceptive activity of N-arachidonoyl-phenolamine (AM404) in the rat: comparison with paracetamol. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 219-229.	1.4	29
46	Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. European Journal of Clinical Pharmacology, 2008, 64, 1-8.	0.8	77
47	Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. Journal of Headache and Pain, 2008, 9, 367-373.	2.5	35
48	Ethanol Causes Neurogenic Vasodilation by TRPV1 Activation and CGRP Release in the Trigeminovascular System of The Guinea Pig. Cephalalgia, 2008, 28, 9-17.	1.8	86
49	Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1224-1229.	0.9	70
50	Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. Journal of Pain, 2007, 8, 737-745.	0.7	132
51	Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology, 2007, 32, 1384-1390.	2.8	115
52	Effect of acute and repeated administration of paracetamol on opioidergic and serotonergic systems in rats. Inflammation Research, 2007, 56, 139-142.	1.6	28
53	A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. European Journal of Neurology, 2006, 13, 1009-1013.	1.7	85
54	Clinical-Biochemical Correlates of Migraine Attacks in Rizatriptan Responders and Non-Responders. Cephalalgia, 2006, 26, 257-265.	1.8	64

#	Article	IF	CITATIONS
55	NF-κB Activity and iNOS Expression in Monocytes from Internal Jugular Blood of Migraine Without Aura Patients During Attacks. Cephalalgia, 2006, 26, 1071-1079.	1.8	45
56	Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: comparison of methods. Journal of Clinical Laboratory Analysis, 2006, 20, 239-244.	0.9	5
57	Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. European Journal of Pharmacology, 2005, 507, 43-48.	1.7	12
58	High prevalence of patent foramen ovale in migraine with aura. Journal of Headache and Pain, 2005, 6, 71-76.	2.5	48
59	A case of a GH–producing pituitary adenoma associated with a unilateral headache with autonomic signs. Journal of Headache and Pain, 2005, 6, 152-155.	2.5	8
60	Differential involvement of central 5-HT 1B and 5-HT 3 receptor subtypes in the antinociceptive effect of paracetamol. Inflammation Research, 2003, 52, 347-352.	1.6	34
61	Central Antinociceptive Activity of Acetylsalicylic Acid Is Modulated by Brain Serotonin Receptor Subtypes. Pharmacology, 2002, 65, 193-197.	0.9	18
62	Triptans: the experience of a clinical pharmacologist in clinical practice. Journal of Headache and Pain, 2001, 2, s103-s106.	2.5	2
63	Long-Term Follow-Up of Patients Treated for Chronic Headache with Analgesic Overuse. Cephalalgia, 2001, 21, 878-883.	1.8	102
64	The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain44Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; DYN, dynorphin; PARA, paracetamol; and ir-DYN, immunoreactive dynorphin Biochemical Pharmacology, 2001, 61, 1409-1416.	2.0	16
65	The effect of Paracetamol on nociception and dynorphin A levels in the rat brain. Neuropeptides, 2001, 35, 110-116.	0.9	25
66	The potentiation of analgesic activity of paracetamol plus morphine involves the serotonergic system in rat brain. Inflammation Research, 1999, 48, 120-127.	1.6	27
67	Acetylsalicylic acid potentiates the antinociceptive effect of morphine in the rat: involvement of the central serotonergic system. European Journal of Pharmacology, 1998, 355, 133-140.	1.7	22
68	Effect of Acetylsalicylic Acid on Formalin Test and on Serotonin System in the Rat Brain. General Pharmacology, 1998, 31, 753-758.	0.7	17
69	The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. European Journal of Pharmacology, 1996, 308, 31-40.	1.7	150
70	Headaches Associated With Chronic Use of Analgesics: A Therapeutic Approach. Headache, 1996, 36, 433-439.	1.8	63
71	High Efficacy and Low Frequency of Headache Recurrence after Oral Sumatriptan. Journal of International Medical Research, 1995, 23, 96-105.	0.4	21
72	Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat. Inflammation Research, 1995, 44, 30-35.	1.6	20

#	Article	IF	CITATIONS
73	Effects of acetylsalicylic acid on serotonin brain receptor subtypes. General Pharmacology, 1995, 26, 737-741.	0.7	11
74	Lack of activity of ketorolac in hot-plate test and serotonin binding capacity of brain membranes in rats. Agents and Actions, 1994, 41, 184-187.	0.7	4
75	International Headache Society Classification: Interobserver Reliability in the Diagnosis of Primary Headaches. Cephalalgia, 1994, 14, 16-20.	1.8	64
76	Effects of Chronic Treatment with Phenazone on the Hot-Plate Test and [³ H]Serotonin Binding Sites in Pons and Cortex Membranes of the Rat. Pharmacology, 1993, 47, 84-90.	0.9	18
77	Physiological parameters and plasma levels after short and long-term propofol infusion. Pharmacological Research, 1992, 25, 220-221.	3.1	Ο
78	The effect of chronic treatment with phenazone on 3h-serotonin binding sites in pons and cortex membranes of the rat. Pharmacological Research, 1992, 25, 53-54.	3.1	2
79	The role of serotonin brain receptors in the analgesic effect of phenazone. Pharmacological Research, 1992, 26, 325.	3.1	Ο
80	Plasma glutathione level in paracetamol daily abuser patients. Changes in plasma cysteine and thiol groups after reduced glutathione administration. Toxicology Letters, 1992, 64-65, 757-761.	0.4	9
81	Pharmacokinetics of naproben after oral administration during and out of migraine attacks. Pharmacological Research, 1992, 25, 208-209.	3.1	Ο
82	Pharmacokinetic of reduced glutathione in man: Effect on plasma cysteine and thiol compounds. Pharmacological Research, 1992, 25, 218-219.	3.1	0
83	Brain serotonin binding capacity, analgesia and drug serum levels after acute treatment with phenazone in rats. Pharmacological Research, 1992, 25, 258-259.	3.1	3
84	Plasma Glutathione Level in Chronic Headache Drug Abuser Patients. Cephalalgia, 1991, 11, 186-187.	1.8	0
85	Determination of naltrexone and 6β-naltrexol in plasma by high-performance liquid chromatography with coulometric detection. Biomedical Applications, 1991, 567, 485-490.	1.7	27
86	Pharmacokinetics of tiaprofenic acid in headache attacks: A preliminary report. Pharmacological Research, 1989, 21, 447-448.	3.1	2
87	Influence of prolonged therapy with flunarizine on glucose, insulin and C-peptide metabolism. Pharmacological Research Communications, 1988, 20, 633-634.	0.2	1